Navigation Links
Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales
Date:2/16/2011

MAHWAH, N.J., Feb. 16, 2011 /PRNewswire/ -- Stryker Corporation's Orthopaedics division today announced at the 2011 American Academy of Orthopaedic Surgeons annual conference the findings of the National Joint Registry for England and Wales, which reports that Stryker's Trident® Cup, Accolade® Hip Stem and Triathlon® Knee System outperformed all competitive products in terms of revision rates for the most frequently used brands.(1,2,3)

"Stryker Orthopaedics focuses on developing products that can address the clinical issues that are most critical to implant performance," said Mike Mogul, Group President, Stryker Orthopaedics. "The National Joint Registry of England and Wales is incredibly important because it demonstrates the performance of implants on the market today and provides surgeon and hospital customers with valuable data, enabling them to make informed purchasing decisions to enhance clinical outcomes."

The 2010 National Joint Registry of England and Wales data revealed that Stryker's Trident® Cup, Accolade® Hip Stem and Triathlon® Knee System all showed the lowest rate of revision when compared with the most frequently used implant systems. According to the registry, Trident® had the lowest revision rate (2.4%) among cementless cups at five years, Accolade® had the lowest revision rate (2.8%) among cementless stems at five years, and Triathlon® had the lowest revision rate (1%) among total knee replacement systems at three years for the second year in a row. (1,2,3)

The Trident® Acetabular System features a patented locking mechanism that outperforms competitive designs(4) in regards to micromotion between cup and liner, and is designed to minimize back-side wear(4) while maximizing jump distance for increased stability(5).  Compatible with Stryker's patented X3® Advanced Bearing Technology, Trident® X3® has demonstrated a 97% reduction in wear compared to conven
'/>"/>

SOURCE Stryker Orthopaedics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion
2. ETEX Corporation Announces Distribution Agreement With Stryker
3. Stryker Statement in Response to the Indictment of Its Biotech Division
4. Stryker to Present at Investor Conferences
5. Stryker Announces Organizational Changes
6. Stryker to Host Conference Call on October 16, 2008
7. New Antimicrobial Webs Sterilize Medical Implants for 14 Days
8. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
9. First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. LifeNet Health Introduces New Sports Medicine Bio-Implants
11. Vermont Surgeon Implants First Accommodating Crystalens in Russia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3
... Primary ... SAN DIEGO, May 27 Favrille, Inc. (Nasdaq:,FVRL) ... trial,of Specifid(TM) following Rituxan(R) in patients with follicular B-cell,non-Hodgkin,s ... Analysis of time to progression (TTP), the primary endpoint ...
... May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... research,and development outsourcing company with operations in ... that it has appointed Dr. Peng Wang ... http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), Prior to ...
... SAN DIEGO, May 23 Amylin Pharmaceuticals,Inc. (Nasdaq: ... Stockholders on,Friday, May 30, 2008 at 11:00 a.m. PT ... the Annual Meeting, Daniel M.,Bradbury, President and Chief Executive ... The live presentation will be Web cast, and ...
Cached Biology Technology:Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 2Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 3WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology 2
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... with fossils led to Natural Sciences and Engineering Research Council ... the oldest known reptile that stands on two legs. ... years of research excellence by joining the ranks of the ... will induct him as a fellow during its annual conference, ...
... pinpointed a natural ingredient of human blood that effectively ... from infecting immune cells and multiplying. The virus blocker ... to full-blown AIDS and—because it works in a different ... of another class of drugs in the fight against ...
... the influenza virus that killed 50 million people in 1918, ... to how the virus killed so quickly and efficiently. , ... a team led by University of Wisconsin-Madison virologist Yoshihiro Kawaoka ... influenza strain - unleashes an immune response that destroys the ...
Cached Biology News:Old dinosaur research leads to new honor 2Discovery of an HIV inhibitor in human blood points to new drug class 2Discovery of an HIV inhibitor in human blood points to new drug class 3Study uncovers a lethal secret of 1918 influenza virus 2Study uncovers a lethal secret of 1918 influenza virus 3
... The Z-Competent E. coli Transformation Buffer ... of competent E. coli cells for simple ... method completely eliminates the requirement for heat ... transformation can be performed by adding DNA ...
Request Info...
Buffer used for mitocapture assays....
... automated perfusion system. For real-time or ... biophysics, electrochemistry, or general liquid-handling research ... millisecond accuracy Run experiments automatically ... accuracy and flexibility Turnkey perfusion ...
Biology Products: